3416-26-0 Usage
Description
LIDOFLAZINE, 98.5% is a pharmaceutical compound with the chemical name 1,1''-(4-Chlorobutylidene)bis(4-fluorobenzene) (C364775). It is a derivative of Zerumbone and is known for its potential anti-tumor effects towards HeLa cancer cells. LIDOFLAZINE, 98.5% is characterized by its white to almost white powder appearance.
Used in Pharmaceutical Industry:
LIDOFLAZINE, 98.5% is used as a coronary vasodilatator for improving blood flow in the coronary arteries, which can help in treating conditions like angina and other heart-related issues.
Used in Cardiology:
LIDOFLAZINE, 98.5% is used as a Ca++ channel activator for regulating the flow of calcium ions through the cell membrane, which can have beneficial effects on heart function and blood pressure.
Used in Oncology:
LIDOFLAZINE, 98.5% is used as a potential anti-tumor agent, particularly against HeLa cancer cells. Its anti-tumor effects are attributed to its ability to modulate various oncological signaling pathways, making it a promising candidate for cancer treatment.
Brand names for LIDOFLAZINE, 98.5% include Angex (Janssen) and Clinium (Ortho-McNeil).
Originator
Clinium,Janssen,W. Germany,1969
Manufacturing Process
A mixture of 6.6 parts 1-[4,4-di-(4-fluoro-phenyl)butyl]-piperazine, 4.33 parts
N-(2-chloro-acetyl)-2,6-dimethyl-aniline, 3.2 parts sodium carbonate, a few
crystals of potassium iodide in 200 parts 4-methyl-2-pentanone is stirred and
refluxed for 70 hours. After cooling there are added 70 parts water. The
organic layer is separated, dried over potassium carbonate, filtered and
evaporated. The oily residue is dissolved in 80 parts diisopropylether and the
solution is filtered hot. After cooling the filtrate at 0°C. the formed solid is
filtered off and recystallired from 80 parts ether, yielding 1-[4,4-di-(4-fluorophenyl)butyl]-4-[(2,6-dimethylanilino-carbonyl)-methyl]-piperazine; MP 159°C
to 161°C.
Therapeutic Function
Coronary vasodilator
Check Digit Verification of cas no
The CAS Registry Mumber 3416-26-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,4,1 and 6 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 3416-26:
(6*3)+(5*4)+(4*1)+(3*6)+(2*2)+(1*6)=70
70 % 10 = 0
So 3416-26-0 is a valid CAS Registry Number.
InChI:InChI=1/C30H35F2N3O/c1-22-5-3-6-23(2)30(22)33-29(36)21-35-19-17-34(18-20-35)16-4-7-28(24-8-12-26(31)13-9-24)25-10-14-27(32)15-11-25/h3,5-6,8-15,28H,4,7,16-21H2,1-2H3,(H,33,36)
3416-26-0Relevant articles and documents
METHODS FOR TREATING CHRONIC FATIGUE SYNDROME AND MYALGIC ENCEPHALOMYELITIS
-
, (2021/03/13)
In one aspect the invention relates to a method of treatment selected from the group consisting of: (a) treating a symptom such as pain in a subject identified or diagnosed as having Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS); (b) treating a symptom such as pain in a subject having dysfunctional TRPM3 ion channel activity; (c) restoring NK cell function in a subject having dysfunctional TRPM3 ion channel activity; and (d) restoring calcium homeostasis in a subject having dysfunctional TRPM3 ion channel activity. The method comprises the step of administering to the subject a therapeutically effective amount of at least one therapeutic compound selected from the group consisting of: (i) an opioid receptor antagonist; (ii) an opioid antagonist; and (iii) a therapeutic compound that restores TRPM3 ion channel activity. In some embodiments the therapeutic compound is naltrexone hydrochloride.
